CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionGross margin is 18.7%, lower than 95% of its Medical Devices peers (median 58.7%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.14%
Annual Rate
CNY 0.20Paid annual
Payout Ratio
57.3%Sustainable
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
10.06BCNY1.08B · vs all stocks (USD)
Trailing P/E
422.80xvs Medical Devices peers
Revenue (TTM)
444.41MCNY66.23M · vs all stocks (USD)
Profit Margin
5.34%vs Medical Devices peers
Beta
-0.0200xvs all stocks
52-Week Change
239.79%vs all stocks
Market Capitalization
10.06BCNY1.08B · vs all stocks (USD)
Enterprise Value
8.81BCNY1.02B · vs all stocks (USD)
Trailing P/E
422.80xvs Medical Devices peers
Price to Sales (TTM)
22.64xvs Medical Devices peers
Price to Book (MRQ)
13.19xvs Medical Devices peers
Enterprise to Revenue
19.83xvs Medical Devices peers
Enterprise to EBITDA
142.57xvs Medical Devices peers
Gross Margin
18.70%vs Medical Devices peers
Profit Margin
5.34%vs Medical Devices peers
Operating Margin
6.33%vs Medical Devices peers
Return on Assets (TTM)
1.75%vs Medical Devices peers
Return on Equity (TTM)
3.13%vs Medical Devices peers
Revenue (TTM)
444.41MCNY66.23M · vs all stocks (USD)
Revenue per Share (TTM)
6.54CNYUpdated Oct 8, 2026Quarterly Revenue Growth
-9.20%vs Medical Devices peers
Gross Profit (TTM)
70.36MCNY10.76M · vs all stocks (USD)
EBITDA (TTM)
24.32MCNY3.62M · vs all stocks (USD)
Net Income (TTM)
23.74MCNY3.54M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
49.80%vs Medical Devices peers
Operating Cash Flow (TTM)
51.85MCNY7.73M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
19.97MCNY3.29M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2000CNYUpdated Oct 8, 2026Trailing Annual Dividend Yield
0.14%vs all stocks
Payout Ratio
57.29%vs Medical Devices peers
Revenue
458.28MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
391.48MCNYFY2025 · Dec 31, 2025Gross Profit
66.80MCNYFY2025 · Dec 31, 2025Operating Income
18.64MCNY2.78M · vs all stocks (USD)
Pre-tax Income
22.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
4.00MCNYFY2025 · Dec 31, 2025Net Income
18.89MCNYFY2025 · Dec 31, 2025EBIT
22.91MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.59MCNYFY2025 · Dec 31, 2025Research & Development
9.74MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
11.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
3.92MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
18.83KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.2778CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.2778CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
68.01MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
68.01MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
18.89MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
33.58MCNYFY2025 · Dec 31, 2025Free Cash Flow
16.52MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
78.18MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
18.89MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-753.97KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
13.37MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.07MCNYFY2025 · Dec 31, 2025Capital Expenditures
-17.06MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.24BCNYFY2025 · Dec 31, 2025Sale of Investments
1.13BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-128.44MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-20.37MCNYFY2025 · Dec 31, 2025Other Financing Charges
-617.86KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-20.99MCNYFY2025 · Dec 31, 2025Shares Outstanding
68.00MSharesUpdated Oct 8, 2026Float Shares
20.60MSharesUpdated Oct 8, 2026% Held by Insiders
69.14%vs all stocks
% Held by Institutions
1.26%vs all stocks
Total Cash (MRQ)
412.95MCNY61.54M · vs all stocks (USD)
Total Cash per Share (MRQ)
6.07CNYUpdated Oct 8, 2026Total Debt (MRQ)
492.41KCNY73.38K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0006xvs Medical Devices peers
Current Ratio (MRQ)
7.27xvs Medical Devices peers
Book Value per Share (MRQ)
11.22CNYUpdated Oct 8, 2026Total Assets
869.04MCNY129.50M · vs all stocks (USD)
Total Current Assets
573.74MCNYFY2025 · Dec 31, 2025Total Liabilities
108.02MCNYFY2025 · Dec 31, 2025Total Non-current Assets
295.30MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
16.51MCNYFY2025 · Dec 31, 2025Total Current Liabilities
91.51MCNYFY2025 · Dec 31, 2025Cash
78.17MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.91MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
81.08MCNYFY2025 · Dec 31, 2025Other Short-term Investments
337.80MCNYFY2025 · Dec 31, 2025Accounts Receivable
89.32MCNYFY2025 · Dec 31, 2025Inventory
41.76MCNYFY2025 · Dec 31, 2025Accounts Payable
60.18MCNYFY2025 · Dec 31, 2025Short-term Debt
254.58KCNYFY2025 · Dec 31, 2025Other Current Liabilities
568.18KCNYFY2025 · Dec 31, 2025Long-term Debt
0.00CNYFY2025 · Dec 31, 2025Common Stock (Book)
68.00MCNYFY2025 · Dec 31, 2025Retained Earnings
266.02MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
761.02MCNY113.41M · vs all stocks (USD)
52-Week Low
31.06CNYUpdated Oct 8, 202652-Week High
148.00CNYUpdated Oct 8, 202652-Week Change
239.79%vs all stocks
Beta
-0.0200xvs all stocks
50-Day MA
103.00CNYUpdated Oct 8, 2026200-Day MA
55.81CNYUpdated Oct 8, 2026Avg 10-Day Volume
2.83MSharesUpdated Oct 8, 2026Avg 30-Day Volume
2.28MSharesUpdated Oct 8, 2026Diluted EPS (TTM)
0.3500CNYUpdated Oct 8, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 18.7%, lower than 95% of its Medical Devices peers (median 58.7%)Significant
Gross margin: 0.19Industry median: 0.59Industry P5: 0.26Peers compared: 60.00
P/E ratio is 327.43×, higher than 95% of its Medical Devices peers (median 27.26×)Significant
P/E ratio: 327.429Industry median: 27.26Industry P95: 90.04Peers compared: 60.00
Debt-to-equity is 0×, lower than 95% of its Medical Devices peers (median 0.22×)Notable
Debt-to-equity: 0.00Industry median: 0.22Industry P5: 0.00Peers compared: 60.00
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 17.54Revenue Growth YoY: -0.09
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Lifetech Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
China Resources Boya Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MannKind Corporation
Tier 1ProductionApproval-Gated PipelineRule
Tandem Diabetes Care Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sequent Scientific Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guangxi Wuzhou Zhongheng Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guilin Sanjin Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shinva Medical Instrument Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Artivion Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Horizon Fixture Group Co., Ltd.
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Butler National Corporation
1 interpretationMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities